← Eichor
Study identifier: NCT06921720 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phosphorus-31 Spectroscopy in Phosphate Diabetes

Condition: Phosphate Diabetes · X-linked Hypophosphatemia  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants65
Who can joinAll sexes, 10 Years to no upper limit
Healthy volunteersYes

About this study

Phosphate diabetes is defined by urinary phosphate wasting due to impaired tubular reabsorption. It can be classified based on either a genetic or acquired origin. Chronic hypophosphatemia causes rickets in children, leading to growth disorders, bone deformities, and bone pain. In adults, it results in osteomalacia, pseudofractures, as well as muscle fatigue and weakness during exertion. X-linked hypophosphatemia (XLH) is a common cause of hereditary rickets linked to renal phosphate loss due to elevated FGF23 levels, most often caused by mutations in the PHEX (Phosphate Regulating Endopeptidase X-Linked) gene. Clinical trials have already demonstrated significant improvements in the quality of life of patients with XLH following the approval of the anti-FGF23 antibody, Burosumab. However, there are other causes of phosphate diabetes, such as tumor-induced osteomalacia (TIO), proximal tubulopathies (Dent disease, cystinosis), or mutations in Npt2a/C. As described above, patients with phosphate diabetes report bone pain and variable muscle fatigue depending on the underlying cause. These symptoms can significantly impact quality of life by limiting physical activities early on. However, standard quality-of-life questionnaires often lack the specificity to accurately assess these symptom-related impairments. At present, the investigators lack objective biomarkers that can quantitatively assess subclinical metabolic abnormalities at the muscular level in these patients. Vari…

This description comes directly from the study's public registry record.

Talk to the study team

Sandrine Lemoine, Pr  ·  +33 472110252  ·  Sandrine.lemoine01@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Hôpital femme mère enfant, hospices civils de LyonBron, FranceNot Yet Recruiting
Hôpital Edouard Herriot, Hospices Civils de LyonLyon, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06921720